Addex Therapeutics Ltd (FRA:APE)

Market Cap	5.43M
Revenue (ttm)	257.68K
Net Income (ttm)	9.07M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	0.60
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	376
Open	0.0540
Previous Close	0.0525
Day's Range	0.0320 - 0.0540
52-Week Range	0.0030 - 0.0810
Beta	n/a
RSI	47.43
Earnings Date	Sep 1, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG...

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: APE

Financial Performance

Financial numbers in CHF